Jiangxi Rimag Group (HKG:2522) saw a 91% decline in attributable profit for the six months ended June 30 to 3.8 million yuan from 43 million yuan during the year-ago period, a Tuesday bourse filing said.
Earnings per share fell to 0.011 yuan during the interim period from 0.127 yuan in the first half of 2023.
Revenue for the Chinese medical imaging company fell by 22% to 413.7 million yuan in the half year from 529.8 million yuan a year prior.
The company attributed the lower revenue mainly to the slowdown of procurement demand from medical institutions leading to a lower revenue from imaging solution services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments